S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-1.16%) $1.619
Gold
(0.30%) $2 349.60
Silver
(-0.43%) $27.52
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

Actualizaciones en tiempo real para Eisai Co., Ltd. [ESALF]

Bolsa: OTC Sector: Healthcare Industria: Drug Manufacturers—Specialty & Generic
Última actualización25 abr 2024 @ 13:54

0.00% $ 40.01

Live Chart Being Loaded With Signals

Commentary (25 abr 2024 @ 13:54):

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures...

Stats
Volumen de hoy 4.00
Volumen promedio 1 120.00
Capitalización de mercado 11.48B
EPS $9.72 ( 2023-11-06 )
Last Dividend $0.603 ( 2023-03-30 )
Next Dividend $0 ( N/A )
P/E 39.22
ATR14 $0 (0.00%)

Eisai Co., Ltd. Correlación

10 Correlaciones Más Positivas
10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Eisai Co., Ltd. Finanzas

Annual 2023
Ingresos: $744.40B
Beneficio Bruto: $543.48B (73.01 %)
EPS: $193.31
FY 2023
Ingresos: $744.40B
Beneficio Bruto: $543.48B (73.01 %)
EPS: $193.31
FY 2022
Ingresos: $756.23B
Beneficio Bruto: $569.79B (75.35 %)
EPS: $167.27
FY 2021
Ingresos: $645.94B
Beneficio Bruto: $484.63B (75.03 %)
EPS: $146.95

Financial Reports:

No articles found.

Eisai Co., Ltd. Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0.555
(N/A)
$0
(N/A)
$0.603
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Eisai Co., Ltd. Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.00 - Decrease likely (20.04%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend $0.784 2014-03-27
Last Dividend $0.603 2023-03-30
Next Dividend $0 N/A
Payout Date 2018-05-24
Next Payout Date N/A
# dividends 18 --
Total Paid Out $11.60 --
Avg. Dividend % Per Year 0.00% --
Score 2.79 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 4.00
Div. Directional Score 7.04 --
Next Divdend (Est)
(2024-09-23)
$0 Estimate 0.00 %
Dividend Stability
0.09 Very Bad
Dividend Score
2.79
Pay Frequency
Annually
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
RWCB Ex Dividend Knight 2023-07-28 Quarterly 0 0.00%
FIDS Ex Dividend Junior 2023-05-18 Annually 0 0.00%
WEGZY Ex Dividend Knight 2023-09-29 Bi-Monthly 0 0.00%
MAORF Ex Dividend Junior 2023-08-17 Sporadic 0 0.00%
CLZNY Ex Dividend Knight 2023-06-09 Annually 0 0.00%
SNMCY Ex Dividend Junior 2023-08-18 Semi-Annually 0 0.00%
HCBC Ex Dividend Knight 2023-08-10 Quarterly 0 0.00%
AMFC Ex Dividend Knight 2023-08-31 Annually 0 0.00%
NHYDY Ex Dividend Knight 2023-05-11 Annually 0 0.00%
CSXXY Ex Dividend Knight 2023-09-15 Semi-Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.06061.5008.7910.00[0 - 0.5]
returnOnAssetsTTM0.03461.2008.8510.00[0 - 0.3]
returnOnEquityTTM0.05461.500-0.504-0.756[0.1 - 1]
payoutRatioTTM1.011-1.00010.00-10.00[0 - 1]
currentRatioTTM2.380.8003.102.48[1 - 3]
quickRatioTTM1.6970.8004.723.78[0.8 - 2.5]
cashRatioTTM1.0251.5005.428.12[0.2 - 2]
debtRatioTTM0.127-1.5007.89-10.00[0 - 0.6]
interestCoverageTTM25.361.0001.7191.719[3 - 30]
operatingCashFlowPerShareTTM215.912.0010.0010.00[0 - 30]
freeCashFlowPerShareTTM166.262.0010.0010.00[0 - 20]
debtEquityRatioTTM0.203-1.5009.19-10.00[0 - 2.5]
grossProfitMarginTTM0.7891.0000.1760.176[0.2 - 0.8]
operatingProfitMarginTTM0.07901.000-0.419-0.419[0.1 - 0.6]
cashFlowToDebtRatioTTM0.3721.0009.049.04[0.2 - 2]
assetTurnoverTTM0.5720.8009.527.62[0.5 - 2]
Total Score10.08

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM39.991.0006.060[1 - 100]
returnOnEquityTTM0.05462.50-0.324-0.756[0.1 - 1.5]
freeCashFlowPerShareTTM166.262.0010.0010.00[0 - 30]
dividendYielPercentageTTM0.01681.5009.580[0 - 0.4]
operatingCashFlowPerShareTTM215.912.0010.0010.00[0 - 30]
payoutRatioTTM1.0111.50010.00-10.00[0 - 1]
pegRatioTTM0.01621.500-3.230[0.5 - 2]
operatingCashFlowSalesRatioTTM0.08261.000-0.4340[0.1 - 0.5]
Total Score4.00

Eisai Co., Ltd.

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Acerca de Señales en Vivo

Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.

Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico